Paul Jenkins

Paul Jenkins is an Associate Professor of Pharmacology at the University of Michigan Medical School, where he leads research focused on neuronal signaling mechanisms, particularly the role of ankyrin proteins and sodium channels in neurodevelopmental and neurodegenerative disorders. His work has substantial impact in understanding autism spectrum disorder mechanisms, with significant findings published in high-impact journals including Neuron.

Dr. Jenkins' research interests center on neuronal excitability, axon initial segment structure and function, and the molecular mechanisms underlying neurodevelopmental disorders. His laboratory investigates how autism risk genes SCN2A and ANK2 converge to shape synaptic plasticity in neocortical pyramidal cells, with particular focus on dendritic excitability. He also explores the role of ankyrin proteins in neuronal polarity and their implications for neurodegenerative diseases such as Alzheimer's and progressive supranuclear palsy. His work utilizes advanced techniques including live two-photon imaging of neuronal microdomains and molecular approaches to study protein scaffolding in neurons.

Analysis of Dr. Jenkins' recent publications reveals a strong focus on the intersection of molecular neuroscience and neurodevelopmental disorders, particularly autism spectrum disorder. His work consistently examines the structural and functional relationships between ion channels and their scaffolding proteins, with implications spanning from basic neuronal signaling mechanisms to clinical applications. The research demonstrates increasing sophistication in imaging techniques and molecular approaches to study neuronal microdomains, with growing emphasis on translational applications for understanding and potentially treating neurodevelopmental conditions.

Dr. Jenkins is actively involved in major collaborative research initiatives, most notably the Heinz C. Prechter Longitudinal Study of Bipolar Disorder, where his expertise in neuronal signaling mechanisms contributes to understanding the biological underpinnings of mood disorders. His laboratory appears to maintain strong collaborative relationships with researchers studying neurodegenerative diseases, particularly those investigating tau pathology in Alzheimer's disease and related tauopathies. His work has generated significant interest in the scientific community, as evidenced by multiple citations and social media engagement with his research findings.